ESMO 2014

Oncology Meeting Resources

26 Sep - 30 Sep 2014, Madrid, Spain

ESMO 2014 Congress

The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist or a radiation oncologist, immunologist or pathologist, practising precision medicine means we are all working towards a common goal – improved patient outcomes. For your convenience and due to the large quantity of information coming from the ESMO 2014 congress, we have split the presentations up by main congress topic to allow you to find the information you need more easily.

Here, you will find the abstracts, posters, PDF presentation and webcasts from ESMO 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Drug Index of ESMO 2014 Abstracts

Special Sessions and Tracks

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...4/The-best-approach-to-oligometastatic-NSCLC

Date: 27 Sep 2014
Presenter: Jaroslaw Kuzdzal
Resources: Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...-cancer-A-randomized-phase-II-clinical-trial

AimThe optimal combination of chemotherapy with radiation therapy for treatment of locally advanced non-small cell lung cancer (NSCLC) remains an open issue. This randomized phase II study compared...

Date: 27 Sep 2014
Presenter: Martina Vrankar
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ly-advanced-Non-small-cell-lung-Cancer-NSCLC

AimLocally advanced NSCLCs are not primarily resectable due to local invasion of vital structure or to the degree of nodal involvement. Intensive chemotherapy induction treatment could improve the...

Date: 27 Sep 2014
Presenter: Laura Bonanno
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...results-in-different-age-groups-70-yrs-70-yr

AimThis single arm multicenter Phase II study showed that Pem-Cis induction chemotherapy (CT) followed by full-dose Pem-Cis + concurrent radiotherapy (RT) was well tolerated and effective in pts with LA NS-NSCLC.

Date: 27 Sep 2014
Presenter: Pilar Garrido Lopez
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...squamous-non-small-cell-lung-cancer-NS-NSCLC

AimThis study was designed to evaluate the response rate of Pem-Cis as preoperative CT in patients with stage IIIAN2 NS NSCLC. The neoadjuvant setting provided the opportunity to obtain tumor tissue...

Date: 27 Sep 2014
Presenter: Ugo Pastorino
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced

http://oncologypro.esmo.org/Meeting-Resourc...ciated-antiemetic-prophylaxis-Santarem-Study

AimNausea and vomiting are some of chemotherapy's most disabling side effects. Our main objective was to compare the impact in quality of life (QoL) of different antiemetics for chemotherapy-induced...

Date: 27 Sep 2014
Presenter: Bárbara Parente
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Supportive Care, Non-Small-Cell Lung Cancer, Locally Advanced

http://oncologypro.esmo.org/Meeting-Resourc...motherapy-in-Stage-III-NSCLC-a-phase-I-study

AimWe have shown that αvß3 integrins control radioresistance, hypoxia and angiogenesis and that co-expression of FGF-2 and αvß3 integrins in the tumors of patients treated with exclusive radio...

Date: 27 Sep 2014
Presenter: Elizabeth Cohen-Jonathan Moyal
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ed-with-neoadjuvant-CCRT-followed-by-surgery

AimThe aim of this study was to evaluate the clinical implications of DNA methylation of tumor suppressor gene in pathologic complete responders in stage IIIA(N2) NSCLC patients treated with neoadjuvant CCRT followed by surgery.

Date: 27 Sep 2014
Presenter: Jae Hyun Kim
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Translational Research, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...-III-non-squamous-non-small-cell-lung-cancer

AimKRAS, a member of the RAS oncogene family, is known to be mutated at exon2 or exon3 in approximately 15%–30% of patients with advanced non-small cell lung cancer (NSCLC).

Date: 27 Sep 2014
Presenter: Shigehiro Yagishita
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Pathology/Molecular Biology, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...nced-lung-cancer-by-emphysema-quantification

AimRadiation pneumonitis (RP) is one of the most crucial adverse events of definitive chemoradiotherapy for the treatment of locally advanced lung cancer. Although chronic obstructive pulmonary disease ...

Date: 27 Sep 2014
Presenter: Shuntaro Tokunaga
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Complications of Treatment, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer